BRISTOL MYERS SQUIBB

Halozyme Therapeutics has agreed to acquire Elektrofi for $750 million upfront plus up to $150 million in milestone payments, gaining access to breakthrough Hypercon microparticle technology.

The FDA has granted Fast Track Designation to BMS-986446, Bristol Myers Squibb's anti-microtubule binding region-tau antibody currently in Phase 2 development for early Alzheimer's disease.

Bristol Myers Squibb, Takeda Pharmaceuticals, and Astex Pharmaceuticals are joining an AI consortium with AbbVie and Johnson & Johnson to train the OpenFold3 drug discovery model.

The FDA will not accept new drug applications during the government shutdown, though it can continue reviewing existing submissions funded by user fees.

Revolution Medicines has appointed Alan Sandler, M.D. as chief development officer to lead development of RAS(ON) inhibitors for RAS-addicted cancers.

Novartis will launch a direct-to-patient platform on November 1, 2025, offering Cosentyx at a 55% discount off list price to cash-paying patients in the US.

AbbVie announced it will launch its ovarian cancer drug Elahere in the UK at a list price matching that in the U.S., following President Trump's most-favored-nation pricing policy demands.

AstraZeneca announced it will offer its diabetes drug Farxiga and asthma drug Airsupra at discounts of up to 70% through a new direct-to-consumer platform launching October 1, 2025.

Bristol Myers Squibb announced that its Phase 3 EXCALIBER-RRMM study evaluating iberdomide in combination with daratumumab and dexamethasone demonstrated statistically significant improvement in minimal residual disease negativity rates compared to standard therapy in relapsed or refractory multiple myeloma patients.

Bristol Myers Squibb announced plans to launch its schizophrenia treatment Cobenfy in the UK in 2026, pricing it at $1,850 monthly or $22,500 annually to match its U.S. list price.